Want to join the conversation?
$BMY 2Q15 Q&A: Fernandez of Leerink asked about features drove recommendations for utilization of CheckMate 12. Francis explained that the focus is really on maintaining efficacy in the combination. As far as efficacy is concerned, focused on durability of responses or overall survival or one year landmark survival and about therapeutic index.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.